Cite
HARVARD Citation
Lewis, K. et al. (n.d.). 307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study. Journal for immunotherapy of cancer. pp. A188-A189. [Online].